# reload+after+2024-01-20 23:38:27.193926
address1§1 Bartholomew Close
city§London
zip§EC1A 7BL
country§United Kingdom
phone§44 20 7206 2650
website§https://www.immupharma.co.uk
industry§Biotechnology
sector§Healthcare
longBusinessSummary§ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
fullTimeEmployees§13
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Timothy Paul McCarthy XIV, FCCA, M.B.A., MBA', 'age': 66, 'title': 'Chairman & CEO', 'yearBorn': 1957, 'fiscalYear': 2022, 'totalPay': 106500, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Timothy Gary Franklin M.B.A., Ph.D.', 'title': 'COO & Director', 'fiscalYear': 2022, 'totalPay': 92500, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Lisa  Baderoon', 'title': 'Head of Investor Relations & Non Executive Director', 'fiscalYear': 2022, 'totalPay': 48000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jean-Marie  Geiger PharmD, MD', 'title': 'Head of Clinical Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Laura  Mauran-Ambrosino', 'title': 'Chief Scientific Officer of ImmuPharma Biotech', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Lara E. Sucheston-Campbell', 'title': 'Head of Clinical & Medical Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Sébastien  R. Goudreau Ph.D.', 'title': 'CEO of ImmuPharma Biotec & Director', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.305
priceToSalesTrailing12Months§101.938034
currency§GBp
forwardEps§-3.39
exchange§LSE
quoteType§EQUITY
shortName§IMMUPHARMA PLC ORD 1P
longName§ImmuPharma plc
firstTradeDateEpochUtc§1067328000
timeZoneFullName§Europe/London
timeZoneShortName§GMT
uuid§f0f0594c-138e-38a4-981a-0e6cc156abf7
recommendationKey§none
quickRatio§0.993
grossMargins§1.0
ebitdaMargins§0.0
trailingPegRatio§None
